EGP Token will be listed at 0.005 $ initially
EastGate Token
creating solution to vital pharmaceutical problems by merging pharmacy with blockchain
Full transparency. More trust, Minimize risk, maximize rewards.
ABOUT EGP
EastGate Biotech Corp
is a dynamic biotech company
We concentrate on altering the delivery ways for well-known drugs, currently administered only by injections, to non-invasive (oral or sublingual) routes. We are developing a technology platform for enhanced drug delivery designed to provide alternative administration of known drugs with the goal of offering patient-friendly products to improve compliance and increase health benefits to fit today's health-conscious lifestyles. At the present time our technology focuses on the delivery of insulin via a liquid insulin mouth solution based on proprietary composition, but we believe that our technology may also be applicable to the delivery of other active pharmaceutical ingredients. We may also develop other novel formulations of pharmaceutical and natural products. The company has identified several biologically active existing molecules that address unmet needs of patients, especially those with ever-growing chronic conditions.
AWESOME SERVICES
Business Model
Technology Platform
EastGate Biotech's Trade Secret proprietary technology is based on a self-nanoemulsifying drug delivery system
EGP Control Panel
Our secondary goal is to leverage our technology for the oral delivery of other active pharmaceutical ingredients for the treatment of non-diabetes indications
Blockchain
Blockchain technology is being incorporated by EastGate Biotech to enhance transparency, security, and traceability in their operations
Research
EastGate Biotech is pioneering research into non-invasive drug delivery methods, focusing on a liquid insulin mouth solution
STATISTIC DATA
EastGate Pharmaceuticals Token Holders
101
Ethereum Network
ABOUT ICO
Road Map
March 2022
Start of the ERC-20 Crypto Platform Development
April 2022
Start of the preparation for the ERC-20 Token Testing
August 2022
Deployment of EGP token on the Main Network
February 2023
Presale Starts
April 2023
Presale ends
November 2023
Collaboration with top pharmaceutical stores across the globe to accept EGP token as payment
July 2024
Training of 10000 pharmacists to make positive impact in the health field
September 2024
Launch of EastGate blockchain
OUR DATA
Token Distribution
EGP Token (EastGate Pharmaceuticals)
Our initial coin offering will run till softcap reached.Full details of the ICO can be found within the platform.
- 60% Token Sale Program
- 8% Reserved Funding
- 15% Team and Founders
- 4% Board Advisors
- 7% Ecosystem Development
- 6% Marketing and Bounty
- Name:EastGate Pharmaceuticals
- Type:ERC20
- Symbol:EGP
- Platform:Ethereum
- General release:100,000,000,000 EGP
General description
EGP token will be released on the basis of Ethereum platform and fully comply with ERC20* standard.
Support of this standard guarantees the compatibility of the token with third-party services (wallets, exchanges, listings, etc.), and provides easy integration.
DATA INFORMATION
Statistic Data
Holders
101
TRANSFERS (EGP)
156
ACCEPTED CURRENCY
10
+ CryptoExchanges
2
FAQ
Frequency Asked Questions
EGP is deployed in Ethereum Mainnet
EGP Token – is unique platform; that is secure, smart and easy-to-use platform, and completely disrupting the way businesses raise capital.
OUR BRAIN
Management
Rose Perri
Chief Executive Officer
Rose C. Perri, President has held management and overseen operations for both private and public companies for the past 20+ years. She has served in a number of start-up biotech companies where her roles included those of principal shareholder, Senior Executive and Board Member. She, along with her late brother, E. Mark Perri, founded Biomin Therapeutics Corporation, a start-up biotech company, in 1990. Biomin was a publically-traded company both on the Toronto and Vancouver Stock Exchanges.
Bill Abajian
Chairman, President and Chief Operating Officer
Mr. William (Bill) D. Abajian brings over 30 years experience in the pharmaceutical and biotechnology industry. He started his career at Electro Nucleonics Inc. in Fairfield, New Jersey where he served as the Vice President of Sales and Marketing between 1981-1988. While at Electro Nucleonics he developed, manufactured and sold blood chemistry and diagnostic kits. Bill founded CPG Inc. in 1988 and served as its Chief Executive Officer until 2002. In 2004, he founded The Abajian Group LLC.
Anna Gluskin
Chairman Emeritus
Anna Gluskin (Chief Executive Officer) has over 30 years’ experience in discovering and developing opportunities in the area of biotechnology pharmaceutical and consumer health products. While she is currently managing her own investments in a number of consumer health products and drug delivery she has served as the Chief Executive Officer and President of Generex Biotechnology Corporation, a company that has developed a proprietary alternative (non-invasive; non-injectable) drug delivery system. Ms. Gluskin was a Founder of Generex Biotechnology Corporation and in her role as CEO she was instrumental in raising over $400 million for the company.
CONTACT US
Get in Touch
Ste. 2203-65 Harbour Square, Toronto,
Ontario, M5J 2L4, Canada
+1-647-692-0652
hello@egptokens.com
Stay connected:
